Angiotensin Receptor-Neprilysin Inhibitor Adherence and Outcomes in Heart Failure with Reduced Ejection Fraction
Open Access
- 17 October 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (1) , 603-612
Abstract
Aims: Whether medication adherence to angiotensin receptor-neprilysin inhibitor (ARNI) in real-world practice is associated with the reduced risk of all-cause mortality or hospitalization relative to that with traditional renin–angiotensin system (RAS) blockade remains unclear. This study investigated the influence of medication adherence of ARNI and traditional RAS blockade in heart failure with reduced ejection fraction (HFrEF). Method: We conducted a nationwide longitudinal cohort study with patients with HFrEF using data from the Korean National Health Insurance Service data (2017–2021) covering the entire population. A total of 13 483 patients with HFrEF who received ARNI were matched 1:1 with 13 483 patients who received traditional RAS blockade using propensity score matching. The primary outcome was a composite of all-cause mortality or any hospitalization within one year. Medication adherence was assessed by calculating the proportion of days covered (PDC) relative to total medication prescribed. ARNI and traditional RAS blockade adherence rates were directly compared to analyse their respective associations with the primary outcome. Results: Patients in the ARNI group had a lower rate of the primary outcome than those in the traditional RAS blockade group [hazard ratio (HR) 0.78; 95% confidence interval (CI) 0.75–0.81; P < 0.001]. Mean PDC values spanning 1 year were 92.6 ± 14.5% and 90.9 ± 17.7% in the ARNI and RAS blockade groups, respectively (P < 0.001). Among patients with PDC ≥ 80%, the risk of primary outcome was significantly lower in the ARNI group than in the RAS blockade group (HR 0.75; 95% CI 0.72–0.78; P < 0.001) while a risk reduction with ARNI was not observed among patients with PDC < 80% (HR 0.95; 95% CI 0.85–1.05; P = 0.313). The beneficial effect was more pronounced among patients with PDC ≥ 80% than that among patients with PDC < 80% (P for interaction <0.001). Conclusions: In a real-world cohort with HFrEF, ARNI was superior to traditional RAS blockade in reducing the risk of all-cause mortality and hospitalization. The benefit of ARNI was pronounced among patients with high medication adherence but not among those with low medication adherence, highlighting the importance of adherence to ARNI treatment for HFrEF. Trial Registration: PARADE-HF ClinicalTrials.gov number, NCT05329727.Keywords
Funding Information
- Novartis Pharmaceutical
- National Research Foundation (RS-2024-00440824)
- National Research Foundation (RS-2024-00340592)
- Korea Disease Control and Prevention Agency (2019-ER6303-00)
- Korea Disease Control and Prevention Agency (2019-ER6303-01)
- Korea Disease Control and Prevention Agency (2019-ER6303-02)
- Korea Disease Control and Prevention Agency (2022-ER0908-00)
- Korea Disease Control and Prevention Agency (2022-ER0908-01)
- Korea Disease Control and Prevention Agency (2022-ER0908-02)
- Korea National Institute of Health (2023ER080600)
- Korea National Institute of Health (2023ER080601)
- Novartis Pharmaceuticals Corporation
- National Research Foundation (RS‐2024‐00440824)
- National Research Foundation (RS‐2024‐00340592)
- Korea Disease Control and Prevention Agency (2019‐ER6303‐00)
- Korea Disease Control and Prevention Agency (2019‐ER6303‐01)
- Korea Disease Control and Prevention Agency (2019‐ER6303‐02)
- Korea Disease Control and Prevention Agency (2022‐ER0908‐00)
- Korea Disease Control and Prevention Agency (2022‐ER0908‐01)
- Korea Disease Control and Prevention Agency (2022‐ER0908‐02)
- Korea National Institute of Health (2023ER080600)
- Korea National Institute of Health (2023ER080601)
This publication has 28 references indexed in Scilit:
- Heart failure quality of care and in‐hospital outcomes during the COVID ‐19 pandemic: findings from the Get With The Guidelines‐Heart Failure registryEuropean Journal of Heart Failure, 2022
- Current Prevalence, Incidence, and Outcomes of Heart Failure with Preserved Ejection FractionHeart Failure Clinics, 2021
- ARNI and MRA Combination in PARAGON-HFJACC: Heart Failure, 2021
- Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HFJACC: Heart Failure, 2021
- Care Gaps in Adherence to Heart Failure GuidelinesJACC: Heart Failure, 2020
- Use of Run-in Periods in Randomized TrialsJAMA, 2020
- Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection FractionJACC: Heart Failure, 2020
- Pharmacy-Based Interdisciplinary Intervention for Patients with Chronic Heart Failure: Results of the PHARM-CHF Randomized Controlled TrialEuropean Journal of Heart Failure, 2019
- Association Between Medication Adherence and the Outcomes of Heart FailurePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
- The use of propensity score methods with survival or time‐to‐event outcomes: reporting measures of effect similar to those used in randomized experimentsStatistics in Medicine, 2013